New Study Demonstrates Anti-Tumor Advantages for Combination Treatment Featuring Peregrine Pharmaceuticals’ PS-Targeting Antibodies in a Preclinical Melanoma Model
November 14, 2016 08:05 ET
|
Peregrine Pharmaceuticals Inc.
-- Promising Results of MSK Study Evaluating Combinations of PS-Targeting Treatment, Anti-PD-1 and Radiation in Mouse B16 Melanoma Model Presented at SITC 2016 -- -- New Data from Second Study...
Biodefense Market size worth USD 17 billion by 2024, with 6.9% CAGR estimation from 2016 to 2024: Global Market Insights Inc.
August 12, 2016 10:00 ET
|
Global Market Insights
Ocean View, Delaware, Aug. 12, 2016 (GLOBE NEWSWIRE) -- Biodefense Market size forecast predicts over USD 17 billion in revenue by 2024; according to the latest research report by Global...
HUPTI Advances Cancer Treatment to Another Level for Cancer Patients With the Addition of Pencil Beam Scanning
February 02, 2016 12:18 ET
|
Hampton University
HAMPTON, Va., Feb. 2, 2016 (GLOBE NEWSWIRE) -- The most precise cancer treatment available is now even sharper at the Hampton University Proton Therapy Institute (HUPTI) thanks to the addition of...
Aeolus Files Investigational New Drug Application With US Food and Drug Administration to Enable Initiation of Human Safety Studies for the Development of AEOL 10150 as a Medical Countermeasure Against Lung Damage From Radiation Exposure
August 20, 2014 13:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Aug 20, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) today announced that it has filed an Investigational New Drug Application (IND) with the Division of...
Aeolus Announces Third Quarter Fiscal Year 2014 Financial Results and Achievements in Lung-ARS Development Program
August 15, 2014 07:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Aug 15, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
Aeolus Announces Additional Data Demonstrating Efficacy of AEOL 10150 as a Medical Countermeasure Against Exposure to Nerve Agents, Sulfur Mustard Gas and Nitrogen Mustard Gas
July 01, 2014 07:30 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jul 1, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Data Presented at 8th Annual NIH Counteract Meeting in Denver
...
Aeolus Announces Publication of Data Demonstrating Efficacy of AEOL 10150 in Animal CEES Model of Mustard Gas Skin Exposure
June 18, 2014 10:39 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jun 18, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) today announced the publication of data from animal model studies demonstrating the efficacy of...
Aeolus Pharmateucticals to Present at LD Micro Invitational Conference
June 02, 2014 08:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jun 2, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in...
Aeolus Announces Second Quarter Fiscal Year 2014 Financial Results and Achievements in Lung-ARS Development Program
May 15, 2014 19:03 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - May 15, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
Aeolus Announces First Quarter Fiscal Year 2014 Financial Results
February 14, 2014 17:30 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Feb 14, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...